X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals Inc., formerly known as Arsanis, Inc., is based in Cambridge, United States.
| Revenue (Most Recent Fiscal Year) | $2.56M |
| Net Income (Most Recent Fiscal Year) | $-37.45M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.13 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.53 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -310.10% |
| Net Margin (Trailing 12 Months) | -311.15% |
| Return on Equity (Trailing 12 Months) | -375.31% |
| Return on Assets (Trailing 12 Months) | -72.87% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.19 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.05 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 19.10 |
| Inventory Turnover (Trailing 12 Months) | 1.93 |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.90 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-3.47 |
| Earnings per Share (Most Recent Fiscal Year) | $-21.32 |
| Diluted Earnings per Share (Trailing 12 Months) | $-14.84 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 11.41M |
| Free Float | 11.16M |
| Market Capitalization | $37.19M |
| Average Volume (Last 20 Days) | 1.56M |
| Beta (Past 60 Months) | 0.60 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.15% |
| Percentage Held By Institutions (Latest 13F Reports) | 72.03% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |